Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Halozyme Therapeutics, Inc.. A complete text table follows the diagram.
Royalties lead Halozyme’s platform, with product sales and collaborations adding the rest.
Swipe to explore
Labels and displayed flow values are reported filing values or exact disclosed subtotals.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Halozyme Therapeutics revenue | 1 | $377M | $376.7M reported quarterly revenue |
| Royalties | 2 | $241M | 64% of total revenues |
| Product sales | 2 | $130M | 35% of total revenues |
| Collaborative agreements | 2 | $5.6M | 1% of total revenues |
| From | To | Value |
|---|---|---|
| Halozyme Therapeutics revenue | Royalties | $241M |
| Halozyme Therapeutics revenue | Product sales | $130M |
| Halozyme Therapeutics revenue | Collaborative agreements | $5.6M |